SHORT COMMUNICATIONAn open-label study of escitalopram in body dysmorphic disorderPhillips, Katharine A.Author Information Butler Hospital and the Department of Psychiatry and Human Behavior, Brown Medical School, Providence, Rhode Island, USA Correspondence and requests for reprints to Katharine Phillips, Butler Hospital, 345 Blackstone Boulevard, Providence, RI 02906, USA Tel: +1 401 4556490; fax: +1 401 4556539; e-mail: [email protected] Received 30 September 2005 Accepted 18 November 2005 International Clinical Psychopharmacology: May 2006 - Volume 21 - Issue 3 - p 177-179 doi: 10.1097/01.yic.0000194378.65460.ef Buy Metrics Abstract Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with reliable and valid measures. BDD symptoms significantly improved (P<0.001), and 73.3% (n=11) of subjects were responders. Of the subjects, 46.7% were very much improved, and 33.3% were much improved. Depressive symptoms, delusionality, functioning and quality of life also significantly improved. Escitalopram was well tolerated. These preliminary data suggest that escitalopram is safe and efficacious for BDD. © 2006 Lippincott Williams & Wilkins, Inc.